Clinical-stage biotechnology company developing precision medicines for kidney diseases
Clinical-stage biotechnology company developing precision medicines for kidney diseases. Its genomics-based approach and proprietary Kidney Genome Atlas platform support target discovery, biomarker development, and selection of patient subsets most likely to respond to treatment. Programs have targeted focal segmental glomerulosclerosis, diabetic nephropathy, and other rare or metabolic kidney diseases.